遠大醫藥(0512.HK)連續第三日上漲創9個月新高
格隆匯1月13日丨繼上個交易日收漲5.41%後,遠大醫藥(0512.HK)今日再度大漲,盤中一度漲9.41%至5.12港元,現報5港元,漲6.84%,暫成交2844萬港元,最新總市值168.88億港元。截至目前該股已連漲3日累漲逾22%。公司1月5日發公告稱獲得全福生技開發的全球首創治療乾眼症的產品BRM421及相關技術的大中華地區的開發及商業化權利。1月6日,國家衞生健康委員會醫政醫管局發佈了《原發性肝癌診療規範(2019年版)》。其中,肝癌治療創新療法90Y微球療法因其良好的療效被列為臨牀用藥之一,為晚期肝細胞癌患者提供優效選擇。遠大醫藥此前聯手鼎暉資本收購澳洲sirtex公司,將其全球獨家治療惡性肝腫瘤的放射介入性醫療產品90Y微球療法——Y-90樹脂微球產品納入旗下,並推動Y-90樹脂微球在中國的註冊及落地工作。業內人士表示隨着國家對創新支持力度的增大,以及藥品器械審評審批提速等,該創新療法有望加速在國內上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.